MeVis Medical Solutions AGFRA:M3V +1.72%66 WACC % is 5.03% as of Jul. 01, 2026, which is 116% above its 10-year median of 2.33. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review. Among 692 Healthcare Providers & Services companies, MeVis Medical Solutions AG ranks better than 78.76% on this metric.
As of today (2026-07-01), MeVis Medical Solutions AG's weighted average cost of capital is 5.03%%. MeVis Medical Solutions AG's ROIC % is 3.35% (calculated using TTM income statement data).
MeVis Medical Solutions AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
MeVis Medical Solutions AG (FRA:M3V) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, MeVis Medical Solutions AG's weighted average cost of capital is 5.03%%. MeVis Medical Solutions AG's ROIC % is 3.35% (calculated using TTM income statement data).
MeVis Medical Solutions AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MeVis Medical Solutions AG's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG WACC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's WACC % distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, MeVis Medical Solutions AG's market capitalization (E) is €44.044 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, MeVis Medical Solutions AG's latest one-year semi-annual average Book Value of Debt (D) is €0 Mil.
a) weight of equity = E / (E + D) = 44.044 / (44.044 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (44.044 + 0) = 0
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 3.0465%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. MeVis Medical Solutions AG's beta is 0.3303.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 3.0465% + 0.3303 * 6% = 5.0283%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Mar. 2026, MeVis Medical Solutions AG's interest expense (positive number) was €-0 Mil. Its total Book Value of Debt (D) is €0 Mil.
Cost of Debt = -0 / 0 = %.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.095 / 1.479 = 6.42%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeVis Medical Solutions AG (FRA:M3V) has a WACC % of 5.03% as of Jul. 01, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on MeVis Medical Solutions AG and its competitors. This is 116% above median its historical median of 2.33. Over the past decade, MeVis Medical Solutions AG's WACC % has ranged from 0.10 to 4.46. According to the industry distribution chart, MeVis Medical Solutions AG ranks #147 out of 692 companies in the Healthcare Providers & Services industry, placing it in the top 21.2%.
Is MeVis Medical Solutions AG's WACC % too high?
MeVis Medical Solutions AG's current WACC % of 5.03% is 116% above median its 10-year median of 2.33. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 4.46. The Healthcare Providers & Services industry median WACC % is 8.50. MeVis Medical Solutions AG's value of 5.03% is 40.8% below this industry median. Based on the distribution chart, MeVis Medical Solutions AG ranks #147 out of 692 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's WACC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MeVis Medical Solutions AG ranks #147 out of 692 companies for WACC %. This places MeVis Medical Solutions AG in the top 21% of its industry — outperforming the majority of peers. The industry median WACC % is 8.50. MeVis Medical Solutions AG's value of 5.03% is 40.8% below this benchmark. Historically, MeVis Medical Solutions AG's own WACC % has ranged from 0.10 to 4.46 over the past decade. While the company's 10-year median is 2.33 vs. the industry median of 8.50, MeVis Medical Solutions AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Healthcare Providers & Services company?
The median WACC % among Healthcare Providers & Services companies is 8.50, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeVis Medical Solutions AG's current WACC % of 5.03% is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on MeVis Medical Solutions AG and its competitors. For the Healthcare Providers & Services industry, the median WACC % is 8.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current WACC % is 5.03%, which is 116% above median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current WACC % of 5.03%. The stock's GF Value™ is €22.52, compared to a current price of €23.60 — trading 4.8% above its estimated fair value. The current WACC % is 5.03%, which is 116% above median its 10-year median of 2.33 and 40.8% below the Healthcare Providers & Services industry median of 8.50. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current WACC % is 5.03% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.60 is trading 4.8% above its estimated GF Value™ of €22.52.
Key valuation signals for FRA:M3V:
WACC %: 5.03% (116% above median its 10-year median of 2.33)
GF Value™: €22.52 vs. price of €23.60 (4.8% above fair value)
Industry Position: 40.8% below the Healthcare Providers & Services median (#147 of 692)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score
Get the complete analysis for FRA:M3V
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
